Horizon Therapeutics says Amgen deal could close earlier than planned if FTC fails to block it
[ad_1] Robert Galbraith | Reuters Horizon Therapeutics expects its $27.8 billion sale to Amgen to close as early as the end of the third quarter, earlier than previously planned — if the Federal Trade Commission’s attempt to block the deal fails — according to a document filed Thursday with the Securities and Exchange Commission. The…